keyword
https://read.qxmd.com/read/38521702/construction-and-validation-of-a-nomogram-predicting-the-overall-survival-benefit-of-unilateral-breast-cancer-patients-undergoing-contralateral-prophylactic-mastectomy
#21
JOURNAL ARTICLE
Luyao Dai, Wenyu Yan, Xueting Ren, Dandan Liu, Lidan Chang, Shuai Lin, Hao Wu, Huafeng Kang, Xiaobin Ma
BACKGROUND: Currently, research on the prognostic factors of unilateral breast cancer (UBC) patients receiving contralateral prophylactic mastectomy (CPM) is limited. This study aimed to construct a new nomogram to predict these patients' overall survival (OS). METHODS: In this retrospective study, 88,477 patients who underwent CPM or unilateral mastectomy (UM) were selected from the Surveillance, Epidemiology, and End Results database. Kaplan-Meier curves and Cox regression analyses were used to determine the difference in the impact of the 2 surgical methods on the prognosis...
February 7, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38520846/worse-histopathology-and-prognosis-in-women-with-breast-cancer-diagnosed-during-the-second-trimester-of-pregnancy
#22
JOURNAL ARTICLE
L Gkekos, F E Lundberg, K Humphreys, I Fredriksson, A L V Johansson
BACKGROUND: Evidence suggests that women with breast cancer diagnosed during pregnancy (PrBC) and within 2 years of delivery (PPBC) have similar survival compared to women diagnosed not near pregnancy if adjusted for stage and subtype. To investigate whether this is true for all subtypes and for both pregnancy and post-delivery periods, we examined clinicopathologic features and survival in women with breast cancer by trimesters and 6-month post-delivery intervals. MATERIALS AND METHODS: Women diagnosed with invasive breast cancer during 1992-2018 at ages 18-44 years were identified in the Swedish Cancer Register, with information on childbirths from the Swedish Multi-Generation Register and clinical data from Breast Cancer Quality Registers...
March 22, 2024: ESMO Open
https://read.qxmd.com/read/38520598/barriers-to-endocrine-therapy-adherence-perspectives-of-black-breast-cancer-survivors-and-their-providers
#23
JOURNAL ARTICLE
Kimberley T Lee, Brian D Gonzalez, Carley Geiss, Hayden J Fulton, Dannelle Charles, Susan T Vadaparampil, N Lynn Henry, Heather S L Jim, Dawn L Hershman, Shelley S Tworoger, Clement K Gwede
PURPOSE: Adherence to oral endocrine therapy (ET) remains an issue for up to half of women prescribed these medications. There is emerging data that Black breast cancer survivors (BCS) have lower rates of ET adherence. Given the disparities in breast cancer recurrence and survival for Black BCS compared to their White counterparts, the goal of this study is to better understand barriers to ET adherence among Black BCS from the patient and provider perspectives. METHODS: In this qualitative study, we conducted semi-structured interviews between October 29, 2021, and March 1, 2023...
March 23, 2024: Journal of Cancer Survivorship: Research and Practice
https://read.qxmd.com/read/38520231/cure-indicators-and-prevalence-by-stage-at-diagnosis-for-breast-and-colorectal-cancer-patients-a-population-based-study-in-italy
#24
JOURNAL ARTICLE
Luigino Dal Maso, Federica Toffolutti, Angela De Paoli, Fabiola Giudici, Silvia Francisci, Lauro Bucchi, Manuel Zorzi, Mario Fusco, Adele Caldarella, Silvia Rossi, Roberta De Angelis, Laura Botta, Alessandra Ravaioli, Claudia Casella, Antonino Musolino, Maria Francesca Vitale, Lucia Mangone, Anna Clara Fanetti, Eva Carpin, Maria Giovanna Burgio Lo Monaco, Enrica Migliore, Maria Letizia Gambino, Margherita Ferrante, Fabrizio Stracci, Cinzia Gasparotti, Giuliano Carrozzi, Rossella Cavallo, Walter Mazzucco, Paola Ballotari, Stefano Ferretti, Giuseppe Sampietro, Roberto Vito Rizzello, Lorenza Boschetti, Giuseppe Cascone, Michael Mian, Maria Teresa Pesce, Daniela Piras, Rocco Galasso, Francesca Bella, Pietro Seghini, Pasquala Pinna, Emanuele Crocetti, Diego Serraino, Stefano Guzzinati
People alive many years after breast (BC) or colorectal cancer (CRC) diagnoses are increasing. This paper aimed to estimate the indicators of cancer cure and complete prevalence for Italian patients with BC and CRC by stage and age. A total of 31 Italian Cancer Registries (47% of the population) data until 2017 were included. Mixture cure models allowed estimation of net survival (NS); cure fraction (CF); time to cure (TTC, 5-year conditional NS >95%); cure prevalence (who will not die of cancer); and already cured (prevalent patients living longer than TTC)...
March 23, 2024: International Journal of Cancer. Journal International du Cancer
https://read.qxmd.com/read/38517602/racial-disparities-in-initiation-of-chemotherapy-among-breast-cancer-patients-with-discretionary-treatment-indication-in-the-state-of-georgia
#25
JOURNAL ARTICLE
Lindsay J Collin, Jade Jones, Rebecca Nash, Jeffrey M Switchenko, Kevin C Ward, Lauren E McCullough
PURPOSE: The majority of breast cancer patients are diagnosed with early-stage estrogen receptor (ER) positive disease. Despite effective treatments for these cancers, Black women have higher mortality than White women. We investigated demographic and clinical factors associated with receipt of chemotherapy among those with a discretionary indication who are at risk for overtreatment. METHODS: Using Georgia Cancer Registry data, we identified females diagnosed with ER positive breast cancer who had a discretionary indication for chemotherapy (2010-2017)...
March 22, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38517442/telephone-based-rehabilitation-intervention-to-optimize-activity-participation-after-breast-cancer-a-randomized-clinical-trial
#26
JOURNAL ARTICLE
Kathleen Doyle Lyons, Stephen B Wechsler, Deborah B Ejem, Courtney J Stevens, Andres Azuero, Sarah Khalidi, Mark T Hegel, Sarah M Dos Anjos, Megan E Codini, Mary D Chamberlin, Jamme L Morency, Jazmine Coffee-Dunning, Karen E Thorp, Danielle Z Cloyd, Susan Goedeken, Robin Newman, Colleen Muse, Gabrielle Rocque, Kimberly Keene, Maria Pisu, Jennifer Echols, Marie A Bakitas
IMPORTANCE: Following treatment, breast cancer survivors face challenges participating in valued activities. OBJECTIVE: To determine whether a telephone-based coaching rehabilitation intervention enhances activity participation in the year following breast cancer treatment. DESIGN, SETTING, AND PARTICIPANTS: In this multisite, single-blind randomized clinical trial (Optimizing Functional Recovery of Breast Cancer Survivors), recruitment occurred between August 28, 2019, and April 30, 2022...
March 4, 2024: JAMA Network Open
https://read.qxmd.com/read/38516853/improving-cervical-cancer-classification-in-pap-smear-images-with-enhanced-segmentation-and-deep-progressive-learning-based-techniques
#27
JOURNAL ARTICLE
Priyanka Mahajan, Prabhpreet Kaur
OBJECTIVE: Cervical cancer, a prevalent and deadly disease among women, comes second only to breast cancer, with over 700 daily deaths. The Pap smear test is a widely utilized screening method for detecting cervical cancer in its early stages. However, this manual screening process is prone to a high rate of false-positive outcomes because of human errors. Researchers are using machine learning and deep learning in computer-aided diagnostic tools to address this issue. These tools automatically analyze and sort cervical cytology and colposcopy images, improving the precision of identifying various stages of cervical cancer...
March 22, 2024: Diagnostic Cytopathology
https://read.qxmd.com/read/38516448/a-rare-organism-causing-cholecystitis-with-bacteremia-in-a-breast-cancer-patient
#28
Mina Ghaly, Alyssa Zakala, Kavya Penmethsa, Kristy D Johnson-Pich
Pantoea , a gram-negative, rod-shaped, anaerobic bacterium, is a rare cause of human disease. Pantoea species have been known to mostly cause pulmonary disease in agricultural workers as they are native to select crops and wild animal furs. However, in very few documented cases, Pantoea has been discovered as the source of nosocomial infections, usually in the setting of an immunocompromised host. This case report details the clinical course of a 62-year-old immunocompromised female with stage 3 breast cancer presenting with acute cholecystitis and bacteremia and the unexpected discovery of Pantoea in peripheral and chemotherapy port blood cultures...
February 2024: Curēus
https://read.qxmd.com/read/38516338/ultra-hypofractionated-one-week-locoregional-radiotherapy-for-patients-with-early-breast-cancer-acute-toxicity-results
#29
JOURNAL ARTICLE
Ivica Ratosa, Angel Montero, Raquel Ciervide, Beatriz Alvarez, Mariola García-Aranda, Jeannette Valero, Xin Chen-Zhao, Mercedes Lopez, Daniel Zucca, Ovidio Hernando, Emilio Sánchez, Miguel Angel de la Casa, Rosa Alonso, Pedro Fernandez-Leton, Carmen Rubio
PURPOSE: Moderate hypofractionated radiotherapy is the standard of care for all patients with breast cancer, irrespective of stage or prior treatments. While extreme hypofractionation is accepted for early-stage tumours, its application in irradiating locoregional lymph nodes remains controversial. MATERIALS AND METHODS: A prospective registry analysis from July 2020 to September 2023 included 276 patients with early-stage breast cancer treated with one-week ultra-hypofractionation (UHF) at 26 Gy in 5 fractions on the whole breast (58...
May 2024: Clinical and Translational Radiation Oncology
https://read.qxmd.com/read/38515208/birc5-expression-by-race-age-and-clinical-factors-in-breast-cancer-patients
#30
JOURNAL ARTICLE
Alina M Hamilton, Andrea Walens, Sarah C Van Alsten, Linnea T Olsson, Joseph Nsonwu-Farley, Xiaohua Gao, Erin L Kirk, Charles M Perou, Lisa A Carey, Melissa A Troester, Yara Abdou
PURPOSE: Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breast cancers are prevalent. EXPERIMENTAL DESIGN: We studied BIRC5 expression in association with clinical and demographic variables and as a predictor of recurrence in 2174 participants in the Carolina Breast Cancer Study (CBCS), a population-based study that oversampled Black (n = 1113) and younger (< 50 years; n = 1137) participants with breast cancer...
March 21, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38513161/cancer-treatment-disparities-in-people-with-hiv-in-the-united-states-2001-2019
#31
JOURNAL ARTICLE
Jennifer K McGee-Avila, Gita Suneja, Eric A Engels, Anne F Rositch, Marie-Josephe Horner, Qianlai Luo, Meredith S Shiels, Jessica Y Islam
PURPOSE: People with HIV (PWH) have worse cancer outcomes, partially because of inequities in cancer treatment. We evaluated cancer treatment disparities among PWH, including an assessment of changes in disparities over time. METHODS: We used data from the HIV/AIDS Cancer Match Study, a population-based HIV and cancer registry linkage to examine diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), and cancers of the cervix, lung, anus, prostate, colon, and female breast...
March 21, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38507751/ribociclib-plus-endocrine-therapy-in-early-breast-cancer
#32
RANDOMIZED CONTROLLED TRIAL
Dennis Slamon, Oleg Lipatov, Zbigniew Nowecki, Nicholas McAndrew, Bozena Kukielka-Budny, Daniil Stroyakovskiy, Denise A Yardley, Chiun-Sheng Huang, Peter A Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock-Ah Im, Manuel Ruiz-Borrego, Sherene Loi, Binghe Xu, Sara Hurvitz, Carlos Barrios, Michael Untch, Rebecca Moroose, Frances Visco, Karen Afenjar, Rodrigo Fresco, Irene Severin, Yan Ji, Farhat Ghaznawi, Zheng Li, Juan P Zarate, Arunava Chakravartty, Tetiana Taran, Gabriel Hortobagyi
BACKGROUND: Ribociclib has been shown to have a significant overall survival benefit in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Whether this benefit in advanced breast cancer extends to early breast cancer is unclear. METHODS: In this international, open-label, randomized, phase 3 trial, we randomly assigned patients with HR-positive, HER2-negative early breast cancer in a 1:1 ratio to receive ribociclib (at a dose of 400 mg per day for 3 weeks, followed by 1 week off, for 3 years) plus a nonsteroidal aromatase inhibitor (NSAI; letrozole at a dose of 2...
March 21, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38507631/histopathological-feature-of-early-onset-breast-cancer-a-comparative-analysis
#33
JOURNAL ARTICLE
Iraj Feizi, Khatereh Isazadehfar, Farshid Sadegzadeh, Paniz Farshadi
BACKGROUND: Breast cancer is one of the most common malignancies among women. In some reports, it has been specified that the diagnosis of breast cancer at an earlier ages worsens the prognosis; this can be attributed to a combination of factors such as advanced stage of disease and late demonstration. Considering different results in last studies, this study's aim was investigation of breast cancer histopathology in two age groups of women under and above 40 years old. MATERIAL AND METHODS: A cross-sectional study was performed on 64 patients with breast cancer referring to hospitals during 2014 and 2015 years...
March 18, 2024: International Tinnitus Journal
https://read.qxmd.com/read/38506978/partial-accelerated-irradiation-with-stereotactic-radiotherapy-at-a-dose-of-30%C3%A2-gy-in-5%C3%A2-fractions-in-early-breast-cancer
#34
JOURNAL ARTICLE
Javier Albendea Roch, Javier T Anchuelo Latorre, M Piedad Galdós Barroso, P Navarrete Solano, Ana Laura Rivero Pérez, Frandeina Pinto Guevara, Mara García Lamela, Javier Olloqui Urroz, M Díaz de Tuesta, Jesús Mazaira, Pedro Muñoz, Pedro J Prada Gómez
PURPOSE: To evaluate feasibility of accelerated partial breast irradiation (APBI) using stereotactic radiotherapy (SBRT) Thirty Gy delivered in 5 fractions for patients with early breast cancer. METHODS: Between January 1st, 2018, and December 31s, 2022, we conducted 117 treatments for patients with early-stage breast cancer. All patients underwent conservative surgery followed by APBI using stereotactic external beam radiotherapy. We analyzed local, regional, distant control, overall survival, toxicity, and cosmetic outcomes...
March 20, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38505146/prognostic-value-of-crp-albumin-lymphocyte-cally-index-in-patients-undergoing-surgery-for-breast-cancer
#35
JOURNAL ARTICLE
Jiaru Zhuang, Shan Wang, Yuan Wang, Yibo Wu, Renjing Hu
PURPOSE: According to the 2023 global cancer data, breast cancer is the most common malignant tumor among women in the world. Its occurrence and development is influenced by inflammation, nutrition, and immune status. Therefore, this study combines C-reactive protein (CRP), albumin, and lymphocyte, which can reflect the above states, to form the CRP-albumin-lymphocyte (CALLY) index, an indicator to evaluate its relationship with overall survival (OS) and disease-free survival (DFS) in breast cancer patients...
2024: International Journal of General Medicine
https://read.qxmd.com/read/38504374/tmem120b-strengthens-breast-cancer-cell-stemness-and-accelerates-chemotherapy-resistance-via-%C3%AE-1-integrin-fak-taz-mtor-signaling-axis-by-binding-to-myh9
#36
JOURNAL ARTICLE
Ran Hu, Yu Cao, Yuanyuan Wang, Tingting Zhao, Kaibo Yang, Mingwei Fan, Mengyao Guan, Yuekang Hou, Jiao Ying, Xiaowen Ma, Ning Deng, Xun Sun, Yong Zhang, Xiupeng Zhang
BACKGROUND: Breast cancer stem cell (CSC) expansion results in tumor progression and chemoresistance; however, the modulation of CSC pluripotency remains unexplored. Transmembrane protein 120B (TMEM120B) is a newly discovered protein expressed in human tissues, especially in malignant tissues; however, its role in CSC expansion has not been studied. This study aimed to determine the role of TMEM120B in transcriptional coactivator with PDZ-binding motif (TAZ)-mediated CSC expansion and chemotherapy resistance...
March 19, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38502313/synchronous-versus-metachronous-spinal-metastasis-a-comparative-study-of-survival-outcomes-following-neurosurgical-treatment
#37
JOURNAL ARTICLE
Mohammed Banat, Anna-Laura Potthoff, Motaz Hamed, Valeri Borger, Jasmin E Scorzin, Tim Lampmann, Harun Asoglu, Logman Khalafov, Frederic C Schmeel, Daniel Paech, Alexander Radbruch, Louisa Nitsch, Johannes Weller, Ulrich Herrlinger, Marieta Toma, Gerrit H Gielen, Hartmut Vatter, Matthias Schneider
PURPOSE: Patients with spinal metastases (SM) from solid neoplasms typically exhibit progression to an advanced cancer stage. Such metastases can either develop concurrently with an existing cancer diagnosis (termed metachronous SM) or emerge as the initial indication of an undiagnosed malignancy (referred to as synchronous SM). The present study investigates the prognostic implications of synchronous compared to metachronous SM following surgical resection. METHODS: From 2015 to 2020, a total of 211 individuals underwent surgical intervention for SM at our neuro-oncology facility...
March 19, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38502243/disabled-2-a-versatile-tissue-matrix-multifunctional-scaffold-protein-with-multifaceted-signaling-unveiling-its-potential-in-the-cancer-battle
#38
REVIEW
Nidhi N Shah, Bhavarth P Dave, Kashvi C Shah, Disha D Shah, Kunal G Maheshwari, Mehul R Chorawala, Priyajeet S Parekh, Maharsh Jani
A multifunctional scaffold protein termed Disabled-2 (Dab2) has recently gained attention in the scientific community and has emerged as a promising candidate in the realm of cancer research. Dab2 protein is involved in a variety of signaling pathways, due to which its significance in the pathogenesis of several carcinomas has drawn considerable attention. Dab2 is essential for controlling the advancement of cancer because it engages in essential signaling pathways such as the Wnt/β-catenin, epidermal growth factor receptor (EGFR), and transforming growth factor-beta (TGF-β) pathways...
March 19, 2024: Naunyn-Schmiedeberg's Archives of Pharmacology
https://read.qxmd.com/read/38502171/machine-learning-approaches-to-predict-symptoms-in-people-with-cancer-systematic-review
#39
REVIEW
Nahid Zeinali, Nayung Youn, Alaa Albashayreh, Weiguo Fan, Stéphanie Gilbertson White
BACKGROUND: People with cancer frequently experience severe and distressing symptoms associated with cancer and its treatments. Predicting symptoms in patients with cancer continues to be a significant challenge for both clinicians and researchers. The rapid evolution of machine learning (ML) highlights the need for a current systematic review to improve cancer symptom prediction. OBJECTIVE: This systematic review aims to synthesize the literature that has used ML algorithms to predict the development of cancer symptoms and to identify the predictors of these symptoms...
March 19, 2024: JMIR Cancer
https://read.qxmd.com/read/38501904/a-genome-wide-association-study-of-endoxifen-serum-concentrations-and-adjuvant-tamoxifen-efficacy-in-early-stage-breast-cancer-patients
#40
JOURNAL ARTICLE
Anabel Beatriz Sanchez-Spitman, Stefan Böhringer, Vincent Olaf Dezentjé, Hans Gelderblom, Jesse Joachim Swen, Henk-Jan Guchelaar
Tamoxifen is part of the standard of care of endocrine therapy for adjuvant treatment of breast cancer. However, survival outcomes with tamoxifen are highly variable. The concentration of endoxifen, the 30-100 times more potent metabolite of tamoxifen and bioactivated by the CYP2D6 enzyme, has been described as the most relevant metabolite of tamoxifen metabolism. A genome-wide association study (GWAS) was performed with the objective to identify genetic polymorphisms associated with endoxifen serum concentration levels and clinical outcome in early-stage breast cancer patients receiving tamoxifen...
March 19, 2024: Clinical Pharmacology and Therapeutics
keyword
keyword
85141
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.